Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Lucentis Compared to Lucentis Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration

Trial Profile

A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Lucentis Compared to Lucentis Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 16 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegpleranib (Primary) ; Ranibizumab
  • Indications Wet age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Sponsors IVERIC bio
  • Most Recent Events

    • 01 Feb 2018 This trial has been completed in Germany (end date: 2017-01-19)
    • 19 Dec 2016 Status changed from active, no longer recruiting to discontinued.
    • 12 Dec 2016 Results of a pooled analysis from OPH1002 and OPH1003 trials published in an OphthoTech Corporation Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top